Stocks › M › MBRX

Moleculin Biotech, Inc. (MBRX) — Earnings Call X-Ray

Our AI read all 10 of MBRX's earnings calls (2022–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q1 2025 · sign up to see
Previous Call Grade
D
Q4 2024
Expected Move
🔒
next 45 days · members
Calls Analyzed
10
2022–2025
Avg Candor
5.9/9
evasion 2.8/9
Promotional ToneCritic AmmunitionFounder-LedVolume Step-UpReads RehearsedQuestion Left Hanging

Call-by-call analysis

🔒 Q1 2025 earnings call 2025-05-14 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor ■/9
Specificity ■/9
Evasion ■/9
Stress ■/9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q1 2025 call grade is ready
The full 37-point AI read of MBRX's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

D Q4 2024 earnings call 2025-03-24 move ±23.4%

Management gave no formal guidance. The delivery was rich in specifics, promotional in tone.

3 analysts · 8 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts✓ Volume step-up ahead⚑ Reads rehearsedFounder-led
Candor 6/9
Specificity 7/9
Evasion 3/9
Confidence 8/9
Uncertainty 5/9
Promotion 8/9
Stress 2/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q3 2024 earnings call 2024-11-11 move ±15.2%

Management gave no formal guidance. The delivery was rich in specifics, promotional in tone.

3 analysts · 7 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedFounder-led
Candor 5/9
Specificity 7/9
Evasion 3/9
Confidence 9/9
Uncertainty 2/9
Promotion 9/9
Stress 4/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q1 2024 earnings call 2024-05-13 move ±14.8%

Management gave no formal guidance. The delivery was rich in specifics, promotional in tone.

Capex: decreasing 3 analysts · 7 questions
⚑ Critic ammunition⚑ Question left hangingFounder-led
Candor 6/9
Specificity 8/9
Evasion 3/9
Confidence 9/9
Uncertainty 4/9
Promotion 9/9
Stress 5/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
From the research question bank
1 more research questions answered NO
NO Answers go deeper than the script

D Q4 2023 earnings call 2024-03-25 move ±26.3%

Management gave no formal guidance. The delivery was rich in specifics, promotional in tone.

2 analysts · 7 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedFounder-led
Candor 6/9
Specificity 7/9
Evasion 3/9
Confidence 9/9
Uncertainty 4/9
Promotion 9/9
Stress 3/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q3 2023 earnings call 2023-11-13 move ±20.8%

Management gave no formal guidance. The delivery was rich in specifics, promotional in tone.

3 analysts · 13 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedFounder-led
Candor 6/9
Specificity 7/9
Evasion 3/9
Confidence 8/9
Uncertainty 5/9
Promotion 8/9
Stress 4/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q2 2023 earnings call 2023-08-11 move ±11.9%

Management gave no formal guidance against contracting margins. The delivery was rich in specifics, promotional in tone.

Margins: contractingCapex: increasing 2 analysts · 5 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedFounder-ledDirection beats results
Candor 6/9
Specificity 7/9
Evasion 4/9
Confidence 8/9
Uncertainty 5/9
Promotion 7/9
Stress 3/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q1 2023 earnings call 2023-05-11 move ±20.5%

Management gave no formal guidance. The delivery was rich in specifics, promotional in tone.

2 analysts · 6 questions
⚑ Critic ammunition⚑ Question left hanging✓ Early product, fast growth⚑ Reads rehearsedFounder-ledDirection beats results
Candor 5/9
Specificity 7/9
Evasion 2/9
Confidence 8/9
Uncertainty 4/9
Promotion 8/9
Stress 4/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q4 2022 2023-03-23 D noneunclearunclear 6/9 3/9
Q3 2022 2022-11-12 D noneunclearcontracting 6/9 2/9

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAC · AAC Holdings'AACAY · AAC Technologies HoldingAACG · ATA Creativity GlobalAADI · Aadi Bioscience, Inc.AALBF · Aalberts N.V.AAOI · Applied Optoelectronics,

← MBNKF   All “M” companies    MBT →

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.